Download PDF

1. Company Snapshot

1.a. Company Description

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally.It operates through Therapy, Plasma & Services, and Other segments.The company offers its products in hematology, clinical immunology, and intensive care medicine areas.


Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis.The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation.In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections.


The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986.The company was founded in 1946 and is headquartered in Dreieich, Germany.As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Show Full description

1.b. Last Insights on BIO3

Biotest Aktiengesellschaft's recent performance was negatively impacted by the company's high operating expenses, which increased by 43% year-over-year in Q2 2024. This was partly due to the expansion of its production capacity and investments in research and development. Additionally, the company's net loss widened to €13.1 million, compared to a net loss of €6.5 million in the same period last year. The high operating expenses and net loss may have weighed on the company's financial performance.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

YIMMUGO® Now Available in the U.S.: Kedrion Biopharma Commercializes a New Ig Therapy for PI

Oct -09

Source:

Card image cap

How Biotest’s Stagnant Price in 2025 Shapes Investor Sentiment After Dividend Growth Concerns

Sep -20

Source:

Card image cap

Societe Generale: shares & voting rights as of 31 August 2025

Sep -09

Source:

Card image cap

Vaisala Corporation: Share Repurchase 9.9.2025

Sep -09

Source:

Card image cap

Assessing Acciona (BME:ANA)'s Valuation After Recent Subtle Moves

Sep -09

Source:

Card image cap

Deutsche Bank (XTRA:DBK): Assessing Valuation After a Period of Quiet Share Price Momentum

Sep -09

Source:

Card image cap

Is Vaisala (HLSE:VAIAS) Undervalued? A Fresh Look at Its Current Valuation

Sep -09

Source:

Card image cap

Has Evotec’s 29.5% Price Drop Created a New Opportunity for 2025?

Sep -09

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.09%)

6. Segments

European Union

Expected Growth: 7.43%

Biotest Aktiengesellschaft's 7.43% growth in the European Union is driven by increasing demand for plasma-based therapies, expansion into new markets, and strategic partnerships. The EU's growing elderly population and rising prevalence of chronic diseases also contribute to the growth. Additionally, the company's investments in research and development, as well as its focus on rare diseases, have led to new product launches and increased sales.

Rest of the World

Expected Growth: 8.5%

The 8.5% growth in the Rest of the World segment of Biotest Aktiengesellschaft is driven by increasing demand for plasma-based therapies, expansion into emerging markets, and strategic partnerships. Additionally, growing healthcare expenditure and investments in healthcare infrastructure in regions such as Asia and Latin America are contributing to this growth.

Stateless

Expected Growth: 8.5%

Stateless from Biotest Aktiengesellschaft's 8.5% growth is driven by increasing demand for plasma-based therapies, expansion into new markets, and strategic partnerships. Additionally, investments in R&D and manufacturing capacity enhancements have improved operational efficiency, contributing to the company's growth momentum.

7. Detailed Products

Biotest Plasma

Biotest Plasma is a pharmaceutical product used to treat various diseases and disorders, including immunodeficiency disorders, bleeding disorders, and infectious diseases.

Biotest Albumin

Biotest Albumin is a pharmaceutical product used to treat hypovolemia, shock, and burns, as well as to prevent and treat bleeding complications.

Biotest Immunoglobulins

Biotest Immunoglobulins are pharmaceutical products used to treat various immune system disorders, including primary immunodeficiency diseases and autoimmune diseases.

Biotest Coagulation Factors

Biotest Coagulation Factors are pharmaceutical products used to treat bleeding disorders, including hemophilia A and B.

Biotest Hyperimmune Globulins

Biotest Hyperimmune Globulins are pharmaceutical products used to treat and prevent infectious diseases, including rabies, tetanus, and hepatitis.

8. Biotest Aktiengesellschaft's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Biotest Aktiengesellschaft is medium due to the presence of alternative products and services in the biotechnology industry.

Bargaining Power Of Customers

The bargaining power of customers for Biotest Aktiengesellschaft is low due to the specialized nature of its products and services, which limits the ability of customers to negotiate prices.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Biotest Aktiengesellschaft is medium due to the presence of multiple suppliers in the market, which limits their bargaining power.

Threat Of New Entrants

The threat of new entrants for Biotest Aktiengesellschaft is high due to the growing demand for biotechnology products and services, which attracts new entrants to the market.

Intensity Of Rivalry

The intensity of rivalry for Biotest Aktiengesellschaft is high due to the presence of established competitors in the biotechnology industry, which leads to intense competition.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 56.09%
Debt Cost 4.85%
Equity Weight 43.91%
Equity Cost 5.14%
WACC 4.98%
Leverage 127.76%

11. Quality Control: Biotest Aktiengesellschaft passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Biotest

A-Score: 5.6/10

Value: 7.6

Growth: 7.4

Quality: 2.4

Yield: 0.0

Momentum: 6.0

Volatility: 10.0

1-Year Total Return ->

View Full Report
Stock-Card
Nanobiotix

A-Score: 5.3/10

Value: 10.0

Growth: 3.1

Quality: 8.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Bavarian Nordic

A-Score: 5.1/10

Value: 6.4

Growth: 9.0

Quality: 7.4

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
MedinCell

A-Score: 5.0/10

Value: 6.0

Growth: 7.0

Quality: 5.9

Yield: 0.0

Momentum: 9.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Galapagos

A-Score: 3.9/10

Value: 8.0

Growth: 2.9

Quality: 5.0

Yield: 0.0

Momentum: 3.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Kuros Biosciences

A-Score: 3.7/10

Value: 4.0

Growth: 6.9

Quality: 4.1

Yield: 0.0

Momentum: 7.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

28.4$

Current Price

28.4$

Potential

-0.00%

Expected Cash-Flows